Clinical Trial: Efficacy and Safety of SPD465 in Adults with ADHD

This study is no longer recruiting patients.

Sponsored by: Shire Pharmaceutical Development
Information provided by: Shire Pharmaceutical Development Identifier: NCT00150579


The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects sleep and how the participants perceive their quality of life.
Condition Intervention Phase
Attention Deficit Disorder with Hyperactivity
 Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
Phase III

MedlinePlus related topics:  Attention Deficit Disorder with Hyperactivity

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Further Study Details: 
Primary Outcomes: The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV) taken at the Baseline visit and all visits thereafter.
Secondary Outcomes: Clinical Global Impression of Improvement scale (CGI-I) - assessed at visits A1 through A7/Early Termination (ET); Time-Sensitive ADHD Symptom Scale (TASS) - completed at the Baseline visit and twice daily throughout the remainder of the subjects participation in this study; Brown ADD Scale (BADDS) - completed at the Baseline and A7/ET visits; Adult ADHD Impact Module (AIM-A) - completed at the Baseline and A7/ET visits; Pittsburgh Sleep Quality Index (PSQI) - completed at every visit from Baseline to study completion/ET
Expected Total Enrollment:  240

Study start: January 2005


Ages Eligible for Study:  18 Years   -   55 Years,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Primary diagnosis of ADHD
  • Baseline ADHD-RS-IV score >= 24
  • Non-pregnant females of childbearing potential must comply with contraceptive restrictions

Exclusion Criteria:

  • Significantly underweight or morbidly obese
  • Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or severe Axis I disorders
  • History of seizure, tic disorder, or a current diagnosis and/or family history of Tourette''''s Disorder

More Information

Study ID Numbers:  SPD465-301
Last Updated:  September 7, 2005
Record first received:  September 6, 2005 Identifier:  NCT00150579
Health Authority: United States: Food and Drug Administration processed this record on 2005-09-13


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us